Enhanced apoptosis by pemetrexed and simvastatin in malignant mesothelioma and lung cancer cells by reactive oxygen species-dependent mitochondrial dysfunction and Bim induction

International Journal of Oncology

Volumn 45, Issue 4, 2014, Pages 1769-1777

  Hwang, Ki Eun ^a   Kim, Young Suk ^a   Hwang, Yu Ri ^a   Kwon, Su Jin ^a   Park, Do Sim ^a   Cha, Byong Ki ^b   Kim, Byoung Ryun ^a   Yoon, Kwon Ha ^a   Jeong, Eun Taik ^a   Kim, Hak Ryul ^a  

^a Wonkwang University School of Medicine   (South Korea)

^b Chonbuk National University Medical School   (South Korea)

Author keywords

Apoptosis; Bim; Mitochondrial dysfunction; Pemetrexed; Reactive oxygen species; Simvastatin

Indexed keywords

ACETYLCYSTEINE; BIM PROTEIN; CASPASE; CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME C; INHIBITOR OF APOPTOSIS PROTEIN; LIPOCORTIN 5; PEMETREXED; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; PUMA PROTEIN; REACTIVE OXYGEN METABOLITE; SIMVASTATIN; SMALL INTERFERING RNA; SURVIVIN; X LINKED INHIBITOR OF APOPTOSIS; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; BCL-2-LIKE PROTEIN 11; GLUTAMIC ACID DERIVATIVE; GUANINE; MEMBRANE PROTEIN; ONCOPROTEIN;

A549 CELL LINE; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL LYSATE; CELL VIABILITY; CONTROLLED STUDY; CYTOSOLIC FRACTION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOBLOTTING; LUNG NON SMALL CELL CANCER; MALIGNANT MESOTHELIOMA; MITOCHONDRIAL MEMBRANE POTENTIAL; MTT ASSAY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; DRUG EFFECTS; DRUG POTENTIATION; GENE EXPRESSION REGULATION; LUNG NEOPLASMS; MESOTHELIOMA; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ACETYLCYSTEINE; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MEMBRANE PROTEINS; MESOTHELIOMA; PROTO-ONCOGENE PROTEINS; REACTIVE OXYGEN SPECIES; SIMVASTATIN;

EID: 84907455981     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2584     Document Type: Article

References (36)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M and Tanimoto M: Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer J Clin Oncol 22: 3852-3859, 2004. (Pubitemid 41079865)
3. Belli C, Fennell D, Giovannini M, Gaudino G and Mutti L: Malignant pleural mesothelioma: current treatments and emerging drugs. Expert Opin Emerg Drugs 14: 423-437, 2009.
4. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C and Paoletti P: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636-2644, 2003. (Pubitemid 46606305)
5. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP and Gandara D: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26: 3543-3551, 2008.
6. Hong J, Kyung SY, Lee SP, Park JW, Jung SH, Lee JI, Park SH, Sym SJ, Park J, Cho EK, Shin DB and Lee JH: Pemetrexed versus gefitinib versus erlotinib in previously treated patients with non-small cell lung cancer. Korean J Intern Med 25: 294-300, 2010.
7. Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ, Patel VF, Andis SL, Bewley JR, Rayl EA, Moroson BA, Beardsley GP, Kohler W, Ratnam M and Schultz RM: LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57: 1116-1123, 1997. (Pubitemid 27138611)
8. Park CK, Kim KS, Oh IJ, Tseden-Ish M, Choi YD, Kwon YS, Kim YI, Lim SC and Kim YC: Efficacy of pemetrexed in relapsed non-small cell lung cancer and thymidylate synthase expression. Tuberc Respir Dis 67: 191-198, 2009.
9. Ramirez JM, Ocio EM, San Miguel JF and Pandiella A: Pemetrexed acts as an antimyeloma agent by provoking cell cycle blockade and apoptosis. Leukemia 21: 797-804, 2007. (Pubitemid 46444565)
10. Lu X, Errington J, Curtin NJ, Lunec J and Newell DR: The impact of p53 status on cellular sensitivity to antifolate drugs. Clin Cancer Res 7: 2114-2123, 2001. (Pubitemid 32994852)
11. Vandermeers F, Hubert P, Delvenne P, Mascaux C, Grigoriu B, Burny A, Scherpereel A and Willems L: Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malingnant mesothelioma. Clin Cancer Res 15: 2818-2828, 2009.
12. Goldstein JL and Brown MS: Regulation of the mevalonate pathway. Nature 343: 425-430, 1990.
13. Chan KK, Oza AM and Siu LL: The statins as anticancer agents. Clin Cancer Res 9: 10-19, 2003. (Pubitemid 36109711)
14. Demierre MF, Higgins PD, Gruber SB, Hawk E and Lippman SM: Statins and cancer prevention. Nat Rev Cancer 5: 930-942, 2005. (Pubitemid 41766782)
15. Holstein SA and Hohl RJ: Synergistic interaction of lovastatin and paclitaxel in human cancer cells. Mol Cancer Ther 1: 141-149, 2001.
16. Feleszko W, Mlynarczuk I, Olszewska D, Jalili A, Grzela T, Lasek W, Hoser G, Korczak-Kowalska G and Jakobisiak M: Lovastatin potentiates antitumor activity of doxorubicin in murine melanoma via an apoptosis-dependent mechanism. Int J Cancer 100: 111-118, 2002. (Pubitemid 34602074)
17. Khanzada UK, Pardo OE, Meier C, Downward J, Seckl MJ and Arcaro A: Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signaling. Oncogene 25: 877-887, 2006. (Pubitemid 43237706)
18. Kozar K, Kaminski R, Legat M, Kopec M, Nowis D, Skierski JS, Koronkiewicz M, Jakobisiak M and Golab J: Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin. Int J Oncol 24: 1149-1157, 2004.
19. Hwang KE, Park C, Kwon SJ, Kim YS, Park DS, Lee MK, Kim BR, Park SH, Yoon KH, Jeong ET and Kim HR: Synergistic induction of apoptosis by sulindac and simvastatin in A549 human lung cancer cells via reactive oxygen species-dependent mitochondrial dysfunction. Int J Oncol 43: 262-270, 2013.
20. Sun JM, Lee KW, Kim JH, Kim YJ, Yoon HI, Lee JH, Lee CT and Lee JS: Efficacy and toxicity of pemetrexed as a third-line treatment of non-small cell lung cancer. Jpn J Clin Oncol 39: 27-32, 2009.
21. Kim KH, Song SY, Lim KH, Han SS, Kim SH, Cho JH, Park CW, Lee S and Lee HY: Interstitial pneumonitis after treatment with pemetrexed for non-small cell lung cancer. Cancer Res Treat 45: 74-77, 2013.
22. Wolf CM and Eastman A: The temporal relationship between protein phosphatase, mitochondrial cytochrome c release. Exp Cell Res 247: 505-513, 1999. (Pubitemid 29394788)
23. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K and Tuschi T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498, 2001. (Pubitemid 32494397)
24. Prevost GP, Pradines A, Brezak MC, Lonchampt MO, Viossat I, Ader I, Toulas C, Kasprzyk P, Gordon T, Favre G and Morgan B: Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of human farnesyltransferase, BIM-46228. Int J Cancer 91: 718-722, 2001. (Pubitemid 32115270)
25. Song JY, Kim CS, Lee JH, Jang SJ, Lee SW, Hwang JJ, Lim C, Lee G, Seo J, Cho SY and Choi J: Dual inhibition of MEK 1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation. Invest New Drugs 31: 1458-1465, 2013.
26. Schulze-Bergkamen H and Krammer PH: Apotosis in cancer-implications for therapy. Semin Oncol 31: 90-119, 2004.
27. Copeland WC, Wachsman JT, Johnson FM and Penta JS: Mitochondrial DNA alterations in cancer. Cancer Invest 20: 557-569, 2002. (Pubitemid 34686350)
28. Kim HR, Yang SH and Jeong ET: Combination treatment with arsenic trioxide and sulindac induces apoptosis of NCI-H157 human lung carcinoma cells via ROS generation with mitochondrial dysfunction. Tuberc Respir Dis 59: 30-38, 2005.
29. Frank S, Gaume B, Bergmann-Leitner ES, Leitner WW, Robert EG, Catez F, Smith CL and Youle RJ: The role of dynamic-related protein 1, a mediator of mitochondrial fission, in apoptosis. Dev Cell 1: 515-525, 2001. (Pubitemid 33586103)
30. Karbowski M, Lee YJ, Gaume B, Jeong SY, Frank S, Nechushtan A, Santel A, Fuller M, Smith CL and Youle RJ: Spatial and temporal association of Bax with mitochondrial fission sites, Drp1, and Mfn2 during apoptosis. J Cell Biol 159: 931-938, 2002. (Pubitemid 36055748)
31. Green DR and Reed JC: Mitochondria and apoptosis. Science 281: 1309-1312, 1998. (Pubitemid 28406816)
32. Li LY, Luo X and Wang X: Endonuclease G is an apoptotic DNase when released from mitochondria. Nature 412: 95-99, 2001. (Pubitemid 32851517)
33. Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A, Bar-Sagi D, Jones SN, Flavell RA and Davis RJ: Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 288: 870-874, 2000. (Pubitemid 30257738)
34. Burdon RH: Control of cell proliferation by reactive oxygen species. Biochem Soc Trans 24: 1028-1032, 1996.
35. Buque A, Muhialdin JSh, Munoz A, Calvo B, Carrera S, Aresti U, Sancho A, Rubio I and Lopez-Vivinco G: Molecular mechanism implicated in pemetrexed-induced apoptosis in human melanoma cells. Mol Cancer 11: 25, 2012.
36. Fiers W, Beyaert R, Declercq W and Vandenabeele P: More than one way to die: apoptosis, necrosis and reactive oxygen damage. Oncogene 18: 7719-7730, 1999. (Pubitemid 30052757)